Loading...
•
Mar 31, 2021
Dyne Therapeutics Q1 2021 Earnings Report
Dyne Therapeutics reported financial results for the first quarter of 2021 and business highlights.
Key Takeaways
Dyne Therapeutics reported a net loss of $25.0 million for the first quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $483.1 million as of March 31, 2021, providing a cash runway expected into the second half of 2024. The company is on track to submit INDs for DM1, DMD and FSHD programs between the fourth quarter of 2021 and the fourth quarter of 2022.
New preclinical data from the DM1 program will be presented at the ASGCT Annual Meeting.
Key leadership appointments were made, strengthening the leadership team.
Cash runway is expected into the second half of 2024.
The company is focused on advancing three programs to the clinic.
Dyne Therapeutics
Dyne Therapeutics
Forward Guidance
Dyne Therapeutics is on track to submit INDs for DM1, DMD and FSHD programs between the fourth quarter of 2021 and the fourth quarter of 2022 and is well-resourced with cash runway expected into the second half of 2024.